Does BCBS Rhode Island cover Wegovy?

What you need to qualify

• Age 12 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent
• BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation
• Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
• Age documentation (>= 12 years for pediatric; >= 18 years for adult)

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: Document covers both Wegovy injection and Wegovy tablet formulations. Wegovy HD (high-dose semaglutide) is also listed as a separate formulation for weight loss in adults. Efficacy should be assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated. Pediatric patients aged 12+ with obesity (BMI >= 95th percentile) are included per FDA labeling.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 12 and older
• BMI of 30 or higher
• BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
• BMI of 23 or higher for patients of Asian descent
• BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation
• Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
• Age documentation (>= 12 years for pediatric; >= 18 years for adult)

Approval and renewal

• To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: Document covers both Wegovy injection and Wegovy tablet formulations. Wegovy HD (high-dose semaglutide) is also listed as a separate formulation for weight loss in adults. Efficacy should be assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated. Pediatric patients aged 12+ with obesity (BMI >= 95th percentile) are included per FDA labeling.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 45 and older
• BMI of 27 or higher
• Established cardiovascular disease (CV death, non-fatal MI, and non-fatal stroke)
• Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Documentation of established cardiovascular disease
• Baseline BMI >= 27 kg/m2
• Confirmation that patient does not have diabetes (SELECT trial basis)

Not covered when

• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended
• SELECT trial excluded patients with diabetes; document notes CV indication is independent of diabetes status per FDA label but trial population was without diabetes

Policy note: The SELECT trial (NCT03574597) enrolled adults >= 45 years with BMI >= 27 kg/m2, established CVD, and without diabetes. The document references this trial as supporting CV risk reduction. The FDA indication covers adults with established CV disease and either obesity or overweight. The clinical rationale notes the CV benefit is 'independent of diabetes status' but the trial itself excluded patients with diabetes, hence excludes_diabetes set to true based on trial population.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 45 and older
• BMI of 27 or higher
• Established cardiovascular disease (CV death, non-fatal MI, and non-fatal stroke)
• Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Documentation of established cardiovascular disease
• Baseline BMI >= 27 kg/m2
• Confirmation that patient does not have diabetes (SELECT trial basis)

Not covered when

• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended
• SELECT trial excluded patients with diabetes; document notes CV indication is independent of diabetes status per FDA label but trial population was without diabetes

Policy note: The SELECT trial (NCT03574597) enrolled adults >= 45 years with BMI >= 27 kg/m2, established CVD, and without diabetes. The document references this trial as supporting CV risk reduction. The FDA indication covers adults with established CV disease and either obesity or overweight. The clinical rationale notes the CV benefit is 'independent of diabetes status' but the trial itself excluded patients with diabetes, hence excludes_diabetes set to true based on trial population.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 18 and older
• Confirmed MASH diagnosis by liver_biopsy, FIB-4, FibroScan_VCTE, MRE, and ELF_test, fibrosis stage F2 to F3
• Lab results confirming eligibility from the last 6 months

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of noncirrhotic MASH
• Evidence of fibrosis stage F2 or F3 via liver biopsy, FIB-4 with confirmatory elastography (VCTE/MRE), or ELF test
• FIB-4 result (primary risk stratification): low-risk < 1.30, indeterminate 1.30–2.67, high-risk > 2.67 (for age > 65, high-risk threshold > 2.0)
• If FIB-4 indeterminate or elevated: confirmatory ELF and/or elastography results
• Confirmation patient does not have cirrhosis

Not covered when

• Cirrhotic MASH excluded (noncirrhotic only per FDA labeling)
• Fibrosis stage F4 (cirrhosis) excluded
• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: FDA indication is for noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). The document outlines a stepwise diagnostic approach: Step 1 FIB-4 (primary risk stratification with cutoffs < 1.30 low, 1.30-2.67 indeterminate, > 2.67 high; age > 65 high threshold > 2.0), Step 2 ELF and/or elastography (VCTE/MRE) for confirmatory testing. ELF cutpoints: < 9.8 low risk, 9.8-11.3 intermediate, >= 11.3 high risk. VCTE cutpoints: < 8 kPa low, 8-12 kPa intermediate, >= 12 kPa high risk/advanced fibrosis. MRE may be used when uncertainty persists. Biopsy reserved for indeterminate/discordant NITs or suspected alternate etiologies. The NASH trial (NCT04822181) enrolled biopsy-confirmed MASH with F2-F3 and NAS >= 4. Imaging lookback set to 6 months for elastography; lab lookback set to 6 months for serum biomarkers (FIB-4, ELF) based on clinical guidance context, though specific lookback periods not explicitly stated in available document text.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

What you need to qualify

• Age 18 and older
• Confirmed MASH diagnosis by liver_biopsy, FIB-4, FibroScan_VCTE, MRE, and ELF_test, fibrosis stage F2 to F3
• Lab results confirming eligibility from the last 6 months

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Diagnosis of noncirrhotic MASH
• Evidence of fibrosis stage F2 or F3 via liver biopsy, FIB-4 with confirmatory elastography (VCTE/MRE), or ELF test
• FIB-4 result (primary risk stratification): low-risk < 1.30, indeterminate 1.30–2.67, high-risk > 2.67 (for age > 65, high-risk threshold > 2.0)
• If FIB-4 indeterminate or elevated: confirmatory ELF and/or elastography results
• Confirmation patient does not have cirrhosis

Not covered when

• Cirrhotic MASH excluded (noncirrhotic only per FDA labeling)
• Fibrosis stage F4 (cirrhosis) excluded
• Concomitant use with other semaglutide-containing products not recommended
• Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: FDA indication is for noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). The document outlines a stepwise diagnostic approach: Step 1 FIB-4 (primary risk stratification with cutoffs < 1.30 low, 1.30-2.67 indeterminate, > 2.67 high; age > 65 high threshold > 2.0), Step 2 ELF and/or elastography (VCTE/MRE) for confirmatory testing. ELF cutpoints: < 9.8 low risk, 9.8-11.3 intermediate, >= 11.3 high risk. VCTE cutpoints: < 8 kPa low, 8-12 kPa intermediate, >= 12 kPa high risk/advanced fibrosis. MRE may be used when uncertainty persists. Biopsy reserved for indeterminate/discordant NITs or suspected alternate etiologies. The NASH trial (NCT04822181) enrolled biopsy-confirmed MASH with F2-F3 and NAS >= 4. Imaging lookback set to 6 months for elastography; lab lookback set to 6 months for serum biomarkers (FIB-4, ELF) based on clinical guidance context, though specific lookback periods not explicitly stated in available document text.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf